Sacramento, CA, Jan. 31, 2018 (GLOBE NEWSWIRE) — A new report has been published on Canbiola, Inc. (OTCPINK: CANB). Canbiola is a Hicksville, New York-based company that is engaged within the sale and distribution of premium hemp-based cannabidiol (CBD) consumer products. Products available include: oils, lotions, creams, gels, moisturizers, vapes, chews, isolates, gel caps, concentrates, and more. Canbiola, Inc. stands apart from other CBD producers in that it utilizes state-of-the-art nanotechnology to break down the CBD molecule sizes to 30-60 nanometers, using ultrasonic sound waves. This process allows for high bioavailability of active ingredients.
The report provides an overview of Canbiola, Inc., its CBD operations, financials, industry analysis, and more. The content also covers the outlook of the global hemp-based CBD market.
Brightfield Group: Hemp CBD Market Worth $1 Billion By 2020
Public opinion continues to shift in favor of cannabis legalization and decriminalization. However, not everyone wants to utilize cannabis in order to get “high,” as associated with the tetrahydrocannabinol (THC) compound found in marijuana. CBDs provide the opportunity for consumers to benefit from the medicinal properties of cannabis without becoming intoxicated. As more US states have legalized recreational cannabis, CBDs have seen their popularity surge in recent years.
According to the market research firm, Brightfield Group, the hemp CBD market is forecast to be worth $1 billion by 2020, which represents a compound annual growth rate (CAGR) of 55% between 2017 and 2020. The market research firm sees the growth in CBDs being fueled by the fact that hemp-derived CBDs are legal in all 50 states and the fact that it has remained “under the radar” of the regulatory uncertainty surrounding the emerging cannabis industry.
Canbiola Sees Massive Sales Growth During Fourth Quarter 2017
After successfully transitioning from a software & technology company to the cannabis industry in 2017, Canbiola is prepared for big results in its first full year focused on CBD business. In a press release from early January 2018, Canbiola issued a shareholder update and review of 2017. The company announced that it has effectively built out its Medical Advisory Board with five highly-qualified medical professionals.
The premium CBD company also announced in the press release that it saw explosive product sales growth during the fourth quarter. “We will report our 4th Quarter and full year (2017) results of operations in our 2017 annual report, but can announce today that product sales (unaudited) for the 4th quarter exceeded the combined product sales (unaudited) for the 3 preceding quarters of 2017.”
Canbiola, Inc. (OTC Pink: CANB) established a manufacturing agreement with a third-party manufacturer during the third quarter 2017. The agreement includes a 10-year option to purchase the manufacturing facility from the third party.
The manufacturing agreement will allow the company to directly manufacture its products (at manufacturers’ cost) and white-label other product with no worry of up-front fees. This essentially makes Canbiola self-sufficient and no longer at the mercy of outside manufacturers. Not to mention, this will allow the company to see a major improvement on its operating margins.
As a result of streamlining its supply chain and manufacturing process, Canbiola recently announced that it is passing the savings onto its customers by cutting product prices by nearly 30% across the board.
Overall, Canbiola, Inc. is a unique CBD company that utilizes proprietary technologies to create a product with high bioavailability of the active ingredients. Furthermore, they are one of the few CBD companies that actually tests their products to ensure quality and a balanced product. Canbiola, Inc. utilizes Dragon Analytical Labs for its product testing needs. As Canbiola, Inc. closed out 2017 with massive sales growth, the company stands prepared for strong results in 2018.
For more information on Canbiola, Inc., please visit https://canbiola.com and https://spotlightgrowth.com//2018/01/30/canbiola-inc-otc-pink-canb-overlooked-unique-cbd-company-high-sales-growth/
SpotlightGrowth.com is a digital hub for micro-caps, small-caps, crowdfunding, cryptocurrency, and other emerging growth investors. SpotlightGrowth.com serves as our media subsidiary and provides insights on small cap companies.
Disclaimer:
Spotlight Growth is compensated, either directly or via a third party, to provide investor relations services for its clients. Spotlight Growth creates exposure for companies through a customized marketing strategy, including design of promotional material, the drafting and editing of press releases and media placement.
All information on featured companies is provided by the companies profiled, or is available from public sources. Spotlight Growth and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The information contained herein is based on external sources that Spotlight Growth believes to be reliable, but its accuracy is not guaranteed. Spotlight Growth may create reports and content that has been compensated by a company or third-parties, or for purposes of self-marketing. Spotlight Growth was compensated five hundred dollars cash for the creation and dissemination of this content.
This material does not represent an investment solicitation. Certain statements contained herein constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may include, without limitation, statements with respect to the Company’s plans and objectives, projections, expectations and intentions. These forward-looking statements are based on current expectations, estimates and projections about the Company’s industry, management’s beliefs and certain assumptions made by management.
The above communication, the attachments and external Internet links provided are intended for informational purposes only and are not to be interpreted by the recipient as a solicitation to participate in securities offerings. Investments referenced may not be suitable for all investors and may not be permissible in certain jurisdictions.
Spotlight Growth and its affiliates, officers, directors, and employees may have bought or sold or may buy or sell shares in the companies discussed herein, which may be acquired prior, during or after the publication of these marketing materials. Spotlight Growth, its affiliates, officers, directors, and employees may sell the stock of said companies at any time and may profit in the event those shares rise in value. For more information on our disclosures, please visit: https://spotlightgrowth.com//disclosures/
